290 related articles for article (PubMed ID: 10090437)
1. Use of diagnostic cluster methodology for therapeutic costing and drug surveillance of HMG-CoA reductase-inhibitor therapy.
Bottorff MB; Yenkowsky JP; Cave DG
Clin Ther; 1999 Jan; 21(1):218-35. PubMed ID: 10090437
[TBL] [Abstract][Full Text] [Related]
2. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.
Cobos A; Jovell AJ; García-Altés A; García-Closas R; Serra-Majem L
Clin Ther; 1999 Nov; 21(11):1924-36. PubMed ID: 10890264
[TBL] [Abstract][Full Text] [Related]
3. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
4. Managed care trends in statin usage.
Bazalo GR
Manag Care; 2001 Oct; 10(10):48-50, 53-9. PubMed ID: 11688111
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257
[TBL] [Abstract][Full Text] [Related]
6. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
Hirsch M; O'Donnell JC; Jones P
Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):18-28. PubMed ID: 15703502
[TBL] [Abstract][Full Text] [Related]
7. Class effects of statins in elderly patients with congestive heart failure: a population-based analysis.
Rinfret S; Behlouli H; Eisenberg MJ; Humphries K; Tu JV; Pilote L
Am Heart J; 2008 Feb; 155(2):316-23. PubMed ID: 18215603
[TBL] [Abstract][Full Text] [Related]
8. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial).
Miller PS; Smith DG; Jones P
Am J Cardiol; 2005 Jun; 95(11):1314-9. PubMed ID: 15904635
[TBL] [Abstract][Full Text] [Related]
10. A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels.
Maclaine GD; Patel H
Int J Clin Pract; 2001 May; 55(4):243-9. PubMed ID: 11406909
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of HMG-CoA reductase inhibition in Canada.
Russell MW; Huse DM; Miller JD; Kraemer DF; Hartz SC
Can J Clin Pharmacol; 2001; 8(1):9-16. PubMed ID: 11283756
[TBL] [Abstract][Full Text] [Related]
12. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
Zhou Z; Rahme E; Pilote L
Am Heart J; 2006 Feb; 151(2):273-81. PubMed ID: 16442888
[TBL] [Abstract][Full Text] [Related]
13. Pharmaco-economic assessment of the HMG-CoA reductase inhibitors.
Smart AJ; Walters L
S Afr Med J; 1994 Dec; 84(12):834-7. PubMed ID: 7570232
[TBL] [Abstract][Full Text] [Related]
14. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel.
Chodick G; Shalev V; Gerber Y; Heymann AD; Silber H; Simah V; Kokia E
Clin Ther; 2008 Nov; 30(11):2167-79. PubMed ID: 19108805
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
Mullins CD; Rattinger GB; Kuznik A; Koren MJ
Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
[TBL] [Abstract][Full Text] [Related]
16. Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
Tran YB; Frial T; Miller PS
Can J Clin Pharmacol; 2007; 14(2):e205-14. PubMed ID: 17556788
[TBL] [Abstract][Full Text] [Related]
17. Lowering copayments: impact of simvastatin patent expiration on patient adherence.
Sedjo RL; Cox ER
Am J Manag Care; 2008 Dec; 14(12):813-8. PubMed ID: 19067498
[TBL] [Abstract][Full Text] [Related]
18. [Porphyria cutanea tarda induced by HMG CoA reductase inhibitors: simvastatin, pravastatin].
Perrot JL; Guy C; Bour Guichenez G; Amigues O; Servoz J; Cambazard F
Ann Dermatol Venereol; 1994; 121(11):817-9. PubMed ID: 7631993
[TBL] [Abstract][Full Text] [Related]
19. Persistence and adherence to cholesterol lowering agents: evidence from Régie de l'Assurance Maladie du Québec data.
Lachaine J; Rinfret S; Merikle EP; Tarride JE
Am Heart J; 2006 Jul; 152(1):164-9. PubMed ID: 16824851
[TBL] [Abstract][Full Text] [Related]
20. Retrospective review of sex differences in the management of dyslipidemia in coronary heart disease: an analysis of patient data from a Maryland-based health maintenance organization.
Cooke CE; Hammerash WJ
Clin Ther; 2006 Apr; 28(4):591-9. PubMed ID: 16750470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
